FDA Approves ZTlido about lidocaine

Sorrento Therapeutics Subsidiary, Scilex, Receives FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for Post-Herpetic Neuralgia Pain.

SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”), and its majority-owned additional, Scilex Pharmaceuticals Inc. (“Scilex”), received approval from the U. S. Food and Drug Administration (FDA) for ZTlido (lidocaine topical system) 1 ) 8%. ZTlido is usually indicated for the comfort of pain associated together with post-herpetic neuralgia (PHN), furthermore referred to as post-shingles pain. ZTlido is the major advancement in pain reducers because of its proprietary aprobacion technology demonstrating 12-hour wear with efficient lidocaine delivery, even during exercise.

“ZTlido was created to fix a trouble that is commonly reported with transdermal/topical patches: they don’t stay on. Based on the adhesion examine results with ZTlido, we all assume that ZTlido product may be welcomed by health-related providers, patients and payers who are looking with regard to an efficient and efficient, nearby pain treatment, ” stated Dr. Henry Ji, Leader and CEO of Sorrento and Scilex. “We also intend to explore the particular expansion of ZTlido in to additional indications and the underlining platform technology of ZTlido for other active pharmaceutical drug ingredients (APIs) and combinations of APIs. As shown by the NDA approval for ZTlido, our group successfully executed on the development arrange for the merchandise and now, looks forwards to executing on our commercial and strategic bijou plans as well. ”

“Topical lidocaine is an important option for healthcare providers to possess in their armamentarium for treating PHN, the difficult-to-treat neuropathic pain, ” explained Dr . Jeff Gudin, Director, Pain Management in addition to Palliative Care, Englewood Hospital and Clinic. “The Centres for Disease Control and Prevention’s guideline of non-opioid treatments for chronic soreness recognizes topical lidocaine as an alternative first-line remedy. ZTlido now offers suppliers and patients this choice. ”

ZTlido’s anhydrous topical ointment strategy is based on a new novel technology that is usually designed to achieve superior adhesion and drug delivery efficiency. ZTlido only requires 36 mg/topical system compared to 700 mg/patch of Lidoderm® (lidocaine patch 5%), the particular US reference product, to be able to achieve the same therapeutic dose of drug. The protection and efficacy of ZTlido was bridged to Lidoderm in comparative pharmacokinetic studies that demonstrated bioequivalence between products.

According to an FDA report of the particular product quality of transdermal drug delivery systems, aprobacion was the most generally noted quality defect of transdermal patches. ¹ Using a very clear need for improved plot adhesion systems, ZTlido had been especially designed to preserve optimum skin contact all through the 12-hour administration period of time. Adhesion is critical to typically the safety and efficacy high quality of a topical program. Simply, the topical system must be in get in touch with with skin to provide the particular drug. ZTlido adhesion efficiency was demonstrated in a new clinical study in fifty-four (54) healthy volunteers where forty-seven (47) subjects (87%) had adhesion scores regarding 0 (≥ 90% adhered; essentially no lift away from the skin) for those critiques performed every 3 several hours during the 12 several hours of administration, and seven (7) subjects (13%) had adhesion scores of 1 (≥ 75% to  < 90% adhered; several edges only lifting away the skin) no less than 1 evaluation, and no subjects had scores of 2 or greater ( < 75% adhered). In typically the same study 91% (49) of the subjects offered with a score of 0 at the conclusion in the 12-hour administration time period. The remaining 5 subjects had a score of just one.

In a separate Period 1 comparative adhesion research in normal healthy subject matter (n=44), ZTlido demonstrated superior adhesion (p  <0. 0001) to Lidoderm at 3 hours that increased over the 12-hour supervision period.

According to latest IMS data, more than 100 million prescription lidocaine patches were bought from typically the US in 2017. Sorrento intends to have Scilex complete the final methods necessary to commercial release of ZTlido in the usa together with the objective to create the product is sold to patients sometime in 2018.

About ZTlido (lidocaine topical system 1.8%)

ZTlido is comprised of a non-aqueous adhesive material containing 1 ) 8% lidocaine, which is applied to a non-woven polyester felt assistance and covered with a polyethylene terephthalate (PET) film release liner. The release liner is perforated in the middle and removed prior to application to skin. The size of the topical strategy is ten cm × 14 cm x 0. 08 centimeter thick. ZTlido is indicated for relief of pain associated with post-herpetic neuralgia. It ought to be applied only to intact skin.

During or immediately after treatment with ZTlido, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, hautentzündung, discoloration, edema, erosions, erythema, exfoliation, flushing, irritation, papules, petechia, pruritus, vesicles, or may be the locus of unusual sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to several hours.

Allergic and anaphylactoid side effects associated with lidocaine, although rare, can occur. These people are seen as a angioedema, bronchospasm, dermatitis, dyspnea, hypersensitivity, laryngospasm, pruritus, shock, and eccema. If they occur, they should be managed by conventional means.

Due to the nature and restriction of spontaneous reports in post-marketing surveillance, causality has not been established for additional reported adverse activities including: Asthenia, confusion, disorientation, dizziness, headache, hyperesthesia, hypoesthesia, lightheadedness, metallic taste, nausea, nervousness, pain exacerbated, paresthesia, somnolence, taste alteration, nausea, visual disturbances such as blurred vision, flushing, ears ringing, and tremor.

Systemic negative reactions following appropriate use of ZTlido are not likely, due to the small dose absorbed. Systemic adverse effects of lidocaine are similar in nature to those observed with other amide local anesthetic providers, including CNS excitation and/or depression (light headedness, anxiousness, apprehension, euphoria, confusion, fatigue, drowsiness, tinnitus, blurred or double vision, vomiting, feelings of warmth, cold or tingling, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest). Excitatory CNS reactions may be brief or not occur in any way, in which case the first outward exhibition may be drowsiness joining into unconsciousness. Cardiovascular indications can include bradycardia, hypotension and cardiovascular collapse leading to arrest.

About Scilex Pharmaceutical drugs Inc.
Scilex, a majority-owned subsidiary of Sorrento positioned in San Diego, California, utilizes on its core, amazing technologies to responsibly develop next generation, branded pharmaceutic products to better control critical conditions and improve the caliber of life of patients and healthcare providers. We all are uncompromising in our focus to become a global pharmaceutical leader committed to social, environmental, economic, and ethical responsibility. Leveraging on our global partnerships, we deliver the lastest of trailblazing products that are responsible by design. The particular Company’s product, ZTlido™ (lidocaine topical system) 1. 8%, is a branded lidocaine topical system formulation for the treatment of alleviating the pain of post-herpetic neuralgia, also referred to as after-shingles pain. Regarding more information visit www.scilexpharma.com.

About Sorrento Therapeutics, Inc.
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into controllable and possibly curable diseases. Sorrento’s multimodal multipronged method to fighting cancer is made possible by its’ intensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”), intracellular concentrating on antibodies (“iTAbs”), antibody-drug conjugates (“ADC”), and clinical period oncolytic virus (“Sephrevir®”).

Sorrento’s commitment to life-enhancing treatments for cancer patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule in Resiniferatoxin (“RTX”) and ZTlido. Resiniferatoxin is completing a phase IB demo in terminal cancer patients.

Forward-Looking Claims

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc. and its subsidiaries under the safe harbor provisions of Segment 21E of the Exclusive Securities Litigation Reform Take action of 1995 and are subject to risks and uncertainties that could cause actual leads to differ materially from those projected. Forward-looking statements include statements regarding ZTlido’s ability to disrupt the patch marketplace, the timing of the accessibility and commercial launch of ZTlido, potential market sizes and success of economic activities, the ability to use additional compounds with the technology, Scilex’ prospects, Sorrento’s strategy, adding other products to the technology and other forward-looking statements. Dangers and uncertainties that could cause our actual results to differ materially and adversely from those portrayed in our forward-looking claims, include, but are not restricted to: that ZTlido might not be commercially successful and other risks that are described in Sorrento’s most recent periodic reports registered with the Securities and Exchange Commission, including Sorrento’s Annual Report on Contact form 10-K for the 12 months ended December 31, 2016, as amended, and following Quarterly Reports on Form 10-Q filed with the Securities and Exchange Percentage, and if applicable, as amended, including the danger factors set forth in those filings. Investors are cautioned not to place excessive reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking declaration in this press release except as required by law.